

TRANSMITTAL LETTER TO THE UNITED STATES
 DESIGNATED/ELECTED OFFICE (DO/EO/US)
 CONCERNING A FILING UNDER 35 U.S.C. 371

05725.0213

08/894788

International Application. No.	International Filing Date	Priority Date Claimed
PCT/FR96/00296	February 26, 1996	February 27, 1995

Title of Invention:

NITRIC OXIDE SYNTHASE INHIBITORS

Applicant For DO/EO/US:

Paolo GIACOMONI

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. [X] This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. [] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. [] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. [X] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. [X] is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. [] has been transmitted by the International Bureau.
 - c. [] is not required, as the application was filed in the United States Receiving Office (RO/US).
6. [X] A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. [] are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. [] have been transmitted by the International Bureau.
 - c. [] have not been made; however, the time limit for making such amendments has NOT expired.
 - d. [X] have not been made and will not be made.
8. [] A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. [] A translation of the annexes (Amended Sheets) to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
11. [X] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [X] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [X] A FIRST preliminary amendment.
 - [] A SECOND or SUBSEQUENT preliminary amendment.
14. [] A substitute specification.
15. [] A change of power of attorney and/or address letter.
16. [] Other items or information:
 - a. [] Verified Small Entity Statement.
 - b. [] Annexes (Amended Sheets) to Intl. Preliminary Examination report.

17. [X] The following fees are submitted:

CALCULATIONS

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO.....\$910.00
 International preliminary examination fee paid to
 USPTO (37 CFR 1.482).....\$700.00
 No international preliminary examination fee paid to
 USPTO (37 CFR 1.482) but international search fee
 paid to USPTO (37 CFR 1.445(a)(2)).....\$770.00
 Neither international preliminary examination fee
 (37 CFR 1.482) nor international search fee
 (37 CFR 1.445(a)(2)) paid to USPTO.....\$1,040.00
 International preliminary examination fee paid to USPTO
 (37 CFR 1.482) and all claims satisfied provisions
 of PCT Article 33(1)-(4).....\$ 96.00

ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 910.00

Surcharge of \$130.00 for furnishing the oath or declaration later than
 [] 20 [] 30 months from the earliest claimed priority date
 (37 CFR 1.492(e)).

Claims	Number Filed	Number Extra	Rate	
Total Claims	34-20=	14	X \$22.00	\$ 308.00
Independent Claims	2 - 3=		X \$80.00	\$
Multiple dependent claim(s) (if applicable)			+\$260.00	\$

TOTAL OF ABOVE CALCULATIONS = \$1218.00

Reduction by 1/2 for filing by small entity, if applicable. Verified
 Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28)

SUBTOTAL = \$1218.00

Processing fee of \$130.00 for furnishing the English translation later
 than [] 20 [] 30 months from the earliest claimed priority date
 (37 CFR 1.492(f)).

TOTAL NATIONAL FEE = \$1218.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The
 assignment must be accompanied by an appropriate cover sheet
 (37 CFR 3.28, 3.31).

\$40.00 per property + \$ 40.00


TOTAL FEES ENCLOSED = \$1258.00

Amount to be
 refunded \$
 charged \$

- a. [X] A check in the amount of **\$1258.00** to cover the above fees is enclosed.
 b. [] Please charge my Deposit Account No. _____ in the amount of \$ _____
 to cover the above fees. A duplicate copy of this sheet is enclosed.
 c. [X] The Commissioner is hereby authorized to charge any additional fees
 which may be required, or credit any overpayment to Deposit Account
 No. 06-0916. A duplicate copy of this sheet is enclosed.

The Commissioner is hereby authorized to charge any other fees due under 37 C.F.R. §1.16
 or §1.17 during the pendency of this application to our Deposit Account No. 06-0916.

SEND ALL CORRESPONDENCE TO:
 Finnegan, Henderson, Farabow
 Garrett & Dunner, L.L.P.
 1300 I Street, N.W.
 Washington, D.C. 20005-3315


 Ernest F. Chapman
 Reg. No. 25,961

05725.0213
 Submitted: August 27, 1997

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Paolo GIACOMONI)	
)	
Serial No.: Not Yet Assigned)	Group Art Unit: Not Yet Assigned
)	
Filed: August 27, 1997)	Examiner: Not Yet Assigned
)	
For: NITRIC OXIDE SYNTHASE)	
INHIBITORS)	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to the examination of this application, please amend the claims as follows:

IN THE CLAIMS:

Please cancel claims 1-30 without prejudice or disclaimer and add new claims 31-64.

--31. A cosmetic or pharmaceutical composition, said composition comprising, in a cosmetically or pharmaceutically acceptable medium,

at least one cosme

tic or pharmaceutical product capable of causing a cutaneous irritant effect, and

at least one nitric oxide synthase inhibitor,

wherein said at least one nitric oxide synthase inhibitor is present in an amount effective to reduce the cutaneous irritant effect of said at least one cosmetic or pharmaceutical product.

32. A composition according to claim 31, wherein said pharmaceutical composition is a dermatological composition.

33. A composition according to claim 31, wherein said at least one nitric oxide synthase inhibitor is present in a concentration ranging from $10^{-6}\%$ to 10% by weight relative to the total weight of the composition.

34. A composition according to claim 33, wherein said at least one nitric oxide synthase inhibitor is present in a concentration ranging from $10^{-4}\%$ to 1% by weight relative to the total weight of the composition.

35. A composition according to claim 31, wherein said at least one cosmetic or pharmaceutical product is a preservative, a surfactant, a perfume, a solvent or a propellant.

36. A composition according to claim 35, wherein said at least one cosmetic or pharmaceutical product is a sunscreen, an α -hydroxy acid, a β -hydroxy acid, an α -

keto acid, a β -keto acid, a retinoid, an anthralin, an anthranoid, a peroxide, minoxidil or one of its derivatives, a lithium salt, an antiproliferative agent, vitamin D or one of its derivatives, vitamin B9 or one of its derivatives, a hair dye, a hair colorant, capsaicin, a perfuming alcoholic solution, an antiperspirant, a depilatory waving active agent, a permanent waving active agent, a depigmenting agent, an antilouse active agent, a detergent or a propigmenting agent.

37. A composition according to claim 36, wherein said β -hydroxy acid is salicylic acid or one of its derivatives.

38. A composition according to claim 36, wherein said at least one cosmetic or pharmaceutical product is a retinoid.

39. A composition according to claim 38, wherein said retinoid is all-trans-retinoic acid, 13-cis-retinoic acid, 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo[b]thiophenecarboxylic acid, 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid, or 3-Pyridinecarboxylic acid.

40. A composition according to claim 36, wherein said vitamin D or one of its derivatives is vitamin D₃, vitamin D₂, 1,25-diOH vitamin D₃, calcipotriol, 1,24-diOH vitamin D₃, 24,25-diOH vitamin D₃, 1-OH vitamin D₂ or 1,24-diOH vitamin D₂.

41. A composition according to claim 40, wherein said 1,24-diOH vitamin D₃ is tacalcitol.

42. A composition according to claim 37, wherein said salicylic acid derivative is 5-n-octanoylsalicylic acid, 5-n-dodecanoylsalicylic acid or one of their esters.

43. A composition according to claim 31, wherein said at least one nitric oxide synthase inhibitor is an inhibitor of constitutive nitric oxide synthase.

44. A composition according to claim 43, wherein said inhibitor of constitutive nitric oxide synthase is an inhibitor of endothelial nitric oxide synthase.

45. A composition according to claim 43, wherein said at least one nitric oxide synthase inhibitor is N^G-monomethyl-L-arginine, the methyl ester of N^G-nitro-L-arginine, N^G-nitro-L-arginine, N^G-amino-L-arginine, or N^G,N^G-dimethylarginine.

46. A composition according to claim 45, wherein said at least one nitric oxide synthase inhibitor is the methyl ester of N^G-nitro-L-arginine, N^G,N^G-dimethylarginine, N^G-nitro-L-arginine or N^G-monomethyl-L-arginine.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000

47. A composition according to claim 31, wherein said composition is formulated in order to be applied topically to the skin, the scalp or the mucous membranes.

48. A method of reducing the cutaneous irritant effect of a topically applied cosmetic or pharmaceutical composition containing at least one cosmetic or pharmaceutical product capable of having an irritant character on the skin, the scalp, the nails or the mucous membranes, said method comprising applying said cosmetic or pharmaceutical product to said skin, scalp, nails or mucous membranes, wherein said cosmetic or pharmaceutical composition further comprises at least one nitric oxide synthase inhibitor in an amount effective to reduce the cutaneous irritant effect of said at least one cosmetic or pharmaceutical product.

49. A method according to claim 48, wherein said at least one nitric oxide synthase inhibitor is present in a concentration ranging from $10^{-6}\%$ to 10% by weight relative to the total weight of the composition.

50. A method according to claim 49, wherein said at least one nitric oxide synthase inhibitor is present in a concentration ranging from $10^{-4}\%$ to 1% by weight relative to the total weight of the composition.

51. A method according to claim 50, wherein said at least one cosmetic or pharmaceutical product is a preservative, a surfactant, a perfume, a solvent or a propellant.

52. A method according to claim 48, wherein said at least one cosmetic or pharmaceutical product is a sunscreen, an α -hydroxy acid, a β -hydroxy acid, an α -keto acid, a β -keto acid, a retinoid, an anthralin, an anthranoid, a peroxide, minoxidil or one of its derivatives, a lithium salt, an antiproliferative agent, vitamin D or one of its derivatives, vitamin B9 or one of its derivatives, a hair dye, a hair colorant, capsaicin, a perfuming alcoholic solution, an antiperspirant, a depilatory waving active agent, a permanent waving active agent, a depigmenting agent, an antilouse active agent, a detergent or a propigmenting agent.

53. A method according to claim 52, wherein said β -hydroxy acid is salicylic acid or one of its derivatives.

54. A method according to claim 52, wherein said at least one cosmetic or pharmaceutical product is a retinoid.

55. A method according to claim 54, wherein said retinoid is all-trans-retinoic acid, 13-cis-retinoic acid, 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-

benzo[b]thiophenecarboxylic acid, 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid, or 3-Pyridinecarboxylic acid.

56. A method according to claim 52, wherein said vitamin D or one of its derivatives is vitamin D₃, vitamin D₂, 1,25-diOH vitamin D₃, calcipotriol, 1,24-diOH vitamin D₃, 24,25-diOH vitamin D₃, 1-OH vitamin D₂ or 1,24-diOH vitamin D₂.

57. A method according to claim 56, wherein said 1,24-diOH vitamin D₃ is tacalcitol.

58. A method according to claim 53, wherein said salicylic acid derivative is 5-n-octanoylsalicylic acid, 5-n-dodecanoylsalicylic acid or one of their esters.

59. A method according to claim 48, wherein said at least one nitric oxide synthase inhibitor is an inhibitor of constitutive nitric oxide synthase.

60. A method according to claim 59, wherein said inhibitor of constitutive nitric oxide synthase is an inhibitor of endothelial nitric oxide synthase.

61. A method according to claim 59, wherein said at least one nitric oxide synthase inhibitor is N^G-monomethyl-L-arginine, the methyl ester of N^G-nitro-L-arginine, N^G-nitro-L-arginine, N^G-amino-L-arginine, or N^G,N^G-dimethylarginine.

62. A method according to claim 61, wherein said at least one nitric oxide synthase inhibitor is the methyl ester of N^G-nitro-L-arginine, N^G,N^G-dimethylarginine, N^G-nitro-L-arginine or N^G-monomethyl-L-arginine.

63. A process for the cosmetic treatment of the skin, the scalp, the nails or the mucous membranes, said process comprising applying a cosmetic composition according to Claim 31 to said skin, scalp, nails or mucous membranes.

64. A process for the pharmaceutical treatment of the skin, the scalp, the nails or the mucous membranes, said process comprising applying a pharmaceutical composition according to Claim 31 to said skin, scalp, nails or mucous membranes.--


REMARKS


Claims 31-64 are presented for examination in this application. Claims 1-30 were canceled without prejudice or disclaimer and their subject matter rewritten in proper U.S. claim format as new claims 31-64. Applicants await an action on the merits.

To the extent any extension of time under 37 C.F.R. § 1.136 is required to obtain entry of this Amendment, such extension is hereby requested. If there are any fees due under 37 C.F.R. § 1.16 or 1.17 which are not enclosed, including any fees required for an extension of time under 37 C.F.R. § 1.136, please charge those fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW
GARRETT & DUNNER, L.L.P.

By:  ^{Reg #} 32,409
for Michele C. Bosch
Registration No. 40,524


Mark D. Sweet
Registration No. P41,469

Dated: August 25, 1997

WO 96/26711

PCT/FR96/00296

NO-SYNTHASE INHIBITORS

The present invention relates to a use of an effective quantity of at least one NO-synthase inhibitor in a cosmetic composition or for the manufacture of a pharmaceutical composition, this inhibitor or the pharmaceutical composition being intended to reduce the cutaneous irritant effect of products used topically in the cosmetic or pharmaceutical field.

It also relates to a cosmetic or pharmaceutical composition comprising an effective quantity of at least one NO-synthase inhibitor and a process of cosmetic treatment using the cosmetic composition according to the invention.

Within the framework of the present invention, the cutaneous irritant effect is a response of the skin which is most often manifested by blotches, pain or pricking, this response being generated by chemical products of natural or synthetic origin which are topically applied to the skin. This irritation is accompanied by impairment of the epithelial structure and/or function which is directly linked to the effect of the product having an irritant character.

Thus, the disruptions induced by a product having an irritant character are followed by a response of the skin which is intense to a greater or lesser degree aimed at restoring the homeostatic equilibrium which is broken or to repair the damages caused. This

response may be infraclinical, that is to say without obvious inflammatory reaction to the naked eye.

However, the reaction which is intense to a greater or lesser degree remains the most usual tissue response to aggression caused by an irritant product and the most disturbing for the user of this product having an irritant character.

When the product having an irritant character reaches the skin, it can react with certain pre-existing substances in the cells and the tissues and/or liberate intracellular substances. These liberated substances may, in turn, become active on other targets in the epithelium or the dermis. Thus, begins the cascade of reactions which, through the recruitment of blood cells and the substances which they liberate, give rise to the irritant process which is characterized mainly by irritation of the skin. This process is manifested in particular in various degrees, depending mainly on the quality and/or quantity of the product applied and/or the user of this product, by dysaesthetic sensations (inflammation, burning sensations, itching or pruritus, sensations of pricking, of twitching and the like), by blotches and/or by an oedema.

These products having an irritant character may be used in cosmetic or pharmaceutical, and more particularly dermatological, compositions quite obviously for other effects. Thus, they are generally

used as active agents, surfactants, preservatives, perfumes, solvents or propellents for the said compositions.

However, because of their irritant character, these products are generally used in very low doses. The use of these products in small quantities may then prove to be of little advantage compared with the use of other products which are less active but less or not irritant and which are therefore used in a larger quantity.

Consequently, there is a need in the cosmetic and pharmaceutical field to find a means allowing these products to be used, without the latter exhibiting an irritant character which can be criticized by the user.

Now, the Applicant has discovered that the NO-synthase inhibitors make it possible to limit, or even suppress, the irritant character of these products.

Thus, the subject of the present invention is the use of an effective quantity of at least one NO-synthase inhibitor in a cosmetic composition or for the manufacture of a pharmaceutical composition, this inhibitor or the pharmaceutical composition being intended to reduce the cutaneous irritant effect of products topically used in the cosmetic or pharmaceutical field.

The cosmetic or pharmaceutical composition comprising the NO-synthase inhibitor may comprise or

In the case where these compounds exist in the same composition, the present invention also relates to a composition for topical, cosmetic or pharmaceutical use, characterized in that it comprises, in a cosmetically or pharmaceutically acceptable medium, an effective quantity of at least one NO-synthase inhibitor and at least one product capable of causing cutaneous irritation.

The present invention also relates to a process of cosmetic treatment, characterized in that it uses the cosmetic composition according to the invention.

The effective quantity of at least one NO-synthase inhibitor according to the invention is a sufficient quantity of at least one NO-synthase inhibitor so that the cutaneous irritant effect decreases or even disappears. Thus, this quantity is variable depending on the quantity and the nature of the product having an irritant character which is applied. However, by way of illustration, a composition according to the invention may comprise at least one NO-synthase inhibitor at a concentration by weight of between $10^{-6}\%$ and 10% of the total weight of the composition and preferably between $10^{-4}\%$ and 1% of the

total weight of the composition.

In the composition according to the invention, the quantity of the product capable of causing a cutaneous irritation may therefore correspond to a quantity which is sufficient to cause a cutaneous irritation if it was used alone (without the NO-synthase inhibitor).

Numerous topically applied products exhibit an irritant character, especially for people (users) with easily irritable skins.

Thus, even the products which are considered to be inert in a cosmetic or pharmaceutical, more particularly dermatological, composition may exhibit an irritant character when they are applied to the skin, the scalp, the nails or the mucous membranes, such as in particular preservatives, surfactants, perfumes, solvents or propellents.

Accordingly, products considered as active agents in cosmetic or pharmaceutical compositions may exhibit an irritant character when they are applied to the skin, the scalp, the nails or the mucous membranes, it is possible to speak of a secondary irritant effect, such as especially some sunscreens, α -hydroxy acids (glycol, lactic, malic, citric, tartaric, mandelic), β -hydroxy acids (salicylic acid and its derivatives), α -keto acids, β -keto acids, retinoids (retinol and its esters, retinal, retinoic acid and its derivatives, retinoids, especially those described in the documents

FR-A-2,570,377, EP-A-199,636, EP-A-325,540, EP-A-402,072), anthralins (dioxyanthranol), anthranoids (for example those described in the document EP-A-319,028), peroxides (especially benzoyl peroxide), minoxidil and its derivatives, lithium salts, antiproliferative agents, such as 5-fluorouracyl or methotrexate, some vitamins, such as vitamin D and its derivatives, vitamin B9 and its derivatives, hair dyes or colorants (para-phenylenediamine and its derivatives, aminophenols), perfuming alcoholic solutions (perfumes, toilet water, aftershave, deodorants), antiperspirants (some aluminium salts), depilatory or permanent waving active agents (thiols), depigmenting agents (hydroquinone), capsaicin, antilouse active agents (pyrethrin), ionic and nonionic detergent agents and propigmenting agents (dihydroxyacetone, psoralens and methylangecilins).

Among these products with a secondary irritant effect, the invention relates more particularly to retinoids.

Among the retinoids, there may be mentioned more particularly all-trans-retinoic acid, 13-cis-retinoic acid, 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo[b]thiophenecarboxylic acid, 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid sold under the name AdapalèneTM by the company Galderma, TazarotèneTM sold by the company Allergan.

Among the vitamin D and its derivatives,

5

their esters.

10

15

20

NO-synthase, the inhibitors of endothelial NO-synthase

are preferred.

Indeed, it seems, without wishing to be tied to any theory of the invention, that the reduction in irritation observed in the present invention is due
5 mainly to the inhibition of the constitutive NO-synthases, and more particularly to the inhibition of the NO-synthase of the endothelial cells.

Thus, among these inhibitors of the constitutive NO-synthase, there may be mentioned more particularly N^G-monomethyl-L-arginine (NMMA), the
10 methyl ester of N^G-nitro-L-arginine (NAME), N^G-nitro-L-arginine (NNA), N^G-amino-L-arginine (NAA), N^G,N^G-dimethylarginine (asymmetric dimethylarginine, called ADMA).

15 NMMA, NAME, NNA and ADMA are preferably used.

The inhibitors of NO-synthase may be used alone or as a mixture.

The inhibitors of NO-synthase may be used both for preventive and curative purposes.

20 The present invention has in particular the advantage of being able to increase the quantity of active agents having an irritant character in cosmetic or pharmaceutical compositions compared with the quantity normally used, for an enhanced efficacy of the
25 said active agents. Thus, the hydroxy acids may be used up to 50% of the weight of the composition or the retinoids up to 5%, without any inconvenience for the user.

The NO-synthase inhibitor(s) may be used by the enteral, parenteral or topical route.

By the topical route, direct application to the skin, the scalp, the nails or the mucous membranes is preferred.

The compositions according to the invention may be provided in any galenic form. These compositions are prepared according to the customary methods.

A cosmetically or dermatologically acceptable medium generally corresponds to a medium which is compatible with the skin, the scalp, the nails or the mucous membranes. The composition comprising the NO-synthase inhibitor may therefore be applied to the face, the neck, the hair and the nails, or any other cutaneous zone of the body (axillary or submammary regions, the elbow bend and the like).

By the topical route, the compositions according to the invention are provided especially in the form of aqueous, aqueous-alcoholic or oily solutions, of dispersions of the lotion or serum type, of anhydrous or lipophilic gels, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O/W) or conversely (W/O), or of suspensions or emulsions of soft, semi-solid or solid consistency of the cream or gel type, or of microemulsions, microcapsules, microparticles or vesicular dispersions of the ionic and/or nonionic type. These compositions

are prepared according to the customary methods.

By the enteral route, the compositions according to the invention may be provided in the form of tablets, gelatin capsules, sugar-coated tablets, 5 syrups, suspensions, solutions, powders, granules, emulsions, microspheres or nanospheres or lipid or polymeric vesicles which allow a controlled release.

By the parenteral route, the compositions may be provided in the form of solutions or suspensions for 10 infusion or injection.

They may also be used on the scalp in the form of aqueous, alcoholic or aqueous-alcoholic solutions, or in the form of creams, gels, emulsions, foams or in the form of compositions for an aerosol 15 also containing a pressurized propelling agent.

The quantities of the various constituents of the compositions according to the invention are those conventionally used in the fields considered.

These compositions constitute in particular 20 shaving foams, cleansing, protective, treatment or care creams for the face, for the hands, for the feet, for the large anatomical folds or for the body, (for example day creams, night creams, make-up removing creams, foundation creams, antisun creams), fluid 25 foundations, make-up removing milks, protective or care body milks, antisun or better still after-sun milks, skin care lotions, gels or foams, such as lotions for cleansing or disinfection, antisun lotions, artificial

5 compositions or compositions for treating certain skin
diseases such as those mentioned above.

10 The compositions may also be packaged in the
form of an aerosol composition also containing a
pressurized propelling agent.

The NO-synthase inhibitors may also be incorporated into various compositions for hair care or treatments, especially shampoos which are optionally antiparasitic, hair setting lotions, treatment lotions, hair styling creams or gels, dyeing (especially oxidation dyeing) compositions optionally in the form of dyeing shampoos, restructuring lotions for the hair, permanent waving compositions (especially compositions for the first stage of a permanent waving), lotions or gels against hair loss, and the like.

The compositions of the invention may also be for dentibuccal use, for example a toothpaste or a mouthwash. In this case, the compositions may contain customary adjuvants and additives for compositions for buccal use and especially surfactants, thickening agents, humectants, polishing agents such as silica,

various active ingredients such as fluorides, in particular sodium fluoride, and optionally sweetening agents such as sodium saccharinate.

When the composition of the invention is an emulsion, the proportion of fatty phase may range from 5% to 80% by weight, and preferably from 5% to 50% by weight relative to the total weight of the composition. The oils, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the cosmetic and pharmaceutical fields. The emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5 to 30% or better still from 0.5 to 20% by weight relative to the total weight of the composition. The emulsion may, in addition, contain lipid vesicles.

When the composition of the invention is an oily gel or a solution, the fatty phase may represent more than 90% of the total weight of the composition.

In a known manner, the composition of the invention may also contain adjuvants common in the cosmetic or pharmaceutical field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, screening agents, bactericides, odour absorbers and colouring matter. The quantities of these various adjuvants are those conventionally used

in the cosmetic or pharmaceutical field, and for example from 0.01% to 10% of the total weight of the composition. These adjuvants, depending on their nature, may be introduced into the fatty phase, into the aqueous phase and/or into the lipid spherules.

As oils which can be used in the invention, there may be mentioned mineral oils (petroleum jelly), vegetable oils (liquid fraction of shea butter, sunflower oil), animal oils (perhydrosqualene), synthetic oils (Purcellin oil), silicone oils (cyclomethicone) and fluorinated oils (perfluoropolyethers). There may also be used, as fatty substances, fatty alcohols, fatty acids (stearic acid), waxes (paraffin, carnauba, beeswax).

As emulsifiers which can be used in the invention, there may be mentioned for example glycerol stearate, polysorbate 60 and the PEG-6/PEG-32/Glycol Stearate mixture sold under the name Tefose^R 63 by the company Gattefosse.

As solvents which can be used in the invention, there may be mentioned the lower alcohols, especially ethanol and isopropanol, propyleneglycol.

As hydrophilic gelling agents, there may be mentioned the carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays, and, as lipophilic gelling agents, there may be mentioned

modified clays such as bentones, metal salts of fatty acids such as aluminium stearates and hydrophobic silica, or ethylcellulose, polyethylene.

As hydrophilic active agents, there may be used proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, starch and plant extracts, especially those of aloe vera.

As lipophilic active agents, there may be used retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides, essential oils.

The NO-synthase inhibitors may, inter alia, be combined with active agents intended especially for the prevention and/or treatment of skin conditions. Among these active agents, there may be mentioned, by way of example:

- agents modulating skin differentiation and/or proliferation and/or pigmentation such as especially retinoids, vitamin D and its derivatives, oestrogens such as estradiol, kojic acid or hydroquinone;
- antibacterials such as clindamycin phosphate, erythromycin or antibiotics of the tetracycline class;
- antiparasitic agents, in particular metronidazole, crotamiton or pyrethrinoids;
- antifungal agents, in particular the compounds belonging to the imidazole class such as econazole, ketoconazole or miconazole or their salts, the polyene

compounds, such as amphotericin B, the compounds of the allylamine family, such as terbinafine, or octopirox;

- steroidal anti-inflammatory agents such as hydrocortisone, betamethasone valerate or clobetasol propionate, or nonsteroidal anti-inflammatory agents such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic acid, acetaminophen or glycyrrhetinic acid;

- anaesthetic agents such as lidocaine hydrochloride and its derivatives;

- antipruriginous agents such as thenaldine, trimeprazine or cyproheptadine;

- antiviral agents such as acyclovir;

- keratolytic agents such as alpha- and beta-hydroxycarboxylic or beta-ketocarboxylic acids, their salts, amides or esters and more particularly alpha-hydroxy acids such as glycolic acid, lactic acid, tartaric acid, citric acid and, in general, fruit acids and beta-hydroxy acids such as salicylic acid and its derivatives, especially alkylated derivatives, such as 5-n-octanoylsalicylic acid;

- anti-free radical agents, such as alpha-tocopherol or its esters, superoxide dismutases, certain metal chelators or ascorbic acid and its esters;

- antiseborrhoeic agents such as progesterone;

- antidandruff agents such as octopirox or zinc pyrithione;

- anti-acne agents such as retinoic acid or benzoyl

peroxide.

Of course persons skilled in the art will be careful to choose the possible compound(s) present in the composition according to the invention so that the properties intrinsically linked to the present invention are not, or not substantially, altered.

The pharmaceutical compositions according to the invention are particularly suitable in the following fields of treatment, these treatments being particularly appropriate when these compositions comprise retinoids:

1) for treating dermatological conditions linked to a keratinization disorder related to differentiation and proliferation especially to treat acne vulgaris, comedo-type acne, polymorphic acne, rosacea, nodulocystic acne, acne conglobata, senile acne, secondary acne such as solar acne, acne medicamentosa or occupational acne,

2) for treating other types of keratinization disorders, especially ichthyosis, ichthyosiform states, Darier's disease, keratosis palmaris et plantaris, leukoplasia and leukoplasiform states, cutaneous or mucosal (buccal) lichen,

3) for treating other dermatological conditions linked to a keratinization disorder with an inflammatory and/or immunoallergic component, and especially all the forms of psoriasis, whether cutaneous, mucosal or ungual, and even psoriatic

function, such as hyperseborrhoea of acne or simple seborrhoea,

11) in the treatment or prevention of cancerous or precancerous states,

5 12) in the treatment of inflammatory conditions such as arthritis,

13) in the treatment of any condition of viral origin at the cutaneous level or in general,

10 14) in the prevention or treatment of alopecia,

15) in the treatment of dermatological or general conditions with an immunological component,

16) in the treatment of conditions of the cardiovascular system, such as arteriosclerosis.

15 The subject of the present invention is, in addition, a process of cosmetic treatment, characterized in that it uses the cosmetic composition according to the invention.

20 Preferably, the process of cosmetic treatment consists in applying to the skin, the scalp and/or the mucuous membranes a composition as described above.

The process of cosmetic treatment of the invention can be carried out in particular by applying the hygiene or cosmetic compositions as defined above, according to the usual technique for using these
25 compositions. For example: application of creams, gels, sera, lotions, make-up removing milks or after-sun compositions to the skin or to dry hair, application of

a hair lotion to wet hair, of shampoo or application of toothpaste to the gums.

In the cosmetic field, the compositions according to the invention are suitable, depending on the active agents contained in this composition, in particular in body and hair hygiene and especially for the treatment of skins which tend to have acne, for hair regrowth, against hair loss, for combating the greasy appearance of the skin or the hair, in protection against the harmful aspects of the sun or in the treatment of physiologically dry skins, for preventing and/or for combating photo-induced or chronologic ageing.

Several examples for obtaining active compounds of formula (I) according to the invention, as well as various concrete formulations based on such compounds will now be given by way of illustration and with no limitation being implied.

EXAMPLE 1

The aim of this example is to demonstrate the oral anti-irritant activity *in vivo* of the methyl ester of N^G-nitro-L-arginine used for curative purposes.

The test used to evaluate this activity is that of mouse ear oedema (Balb/C mouse) induced by topical application of 0.01% by weight of 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo[b]thiophenecarboxylic acid. According to this model, the response to a topical application of

2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-
6-benzo[b]thiophenecarboxylic acid to the ear results
in an increase in the thickness of the ear which is
maximum 5 days after the application. This increase in
5 the thickness of the mouse ear appears to be due to an
increase in the thickness of the epidermis and to the
appearance of a dermal oedema. This response can
therefore be easily measured with the aid of an
apparatus, such as the oditest.

10 The exact operating procedure is the
following: 10 mice are first treated with the active
product having an irritant character by topically
applying to one of their ears at time $t=0$ with 20 μ l of
an acetone solution containing 0.01% by weight of
15 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-
6-benzo[b]thiophenecarboxylic acid. 5 (=group 2) of the
10 mice thus treated are made to ingest orally N^G -
nitro-L-arginine methyl ester in drinking water from
 $t=0$ and once per day for 11 days (N^G -nitro-L-arginine
20 methyl ester concentration of 1 mg/ml, that is to say
170 \pm 40 mg/kg per day). The 5 mice which did not
ingest the N^G -nitro-L-arginine methyl ester constitute
group 1. The oedematous response is quantified by
measurement of the thickness of the ear. The results
25 are then expressed as % increase in the thickness of
the mouse ear compared to the increase in thickness
observed on the other ear which, for its part, was
treated (under the same conditions as above) with only

an acetone solution without active agent (control or reference ear).

The results obtained are as follows:

After 5 days of treatment, the increase in
5 the thickness of the mouse ear is at its maximum (100%)
for group 1 and is 70% for group 2.

The above results clearly demonstrate a 30%
inhibition of the ear oedema for the mice treated with
this NO-synthase inhibitor.

10 Furthermore, no sign of toxicity was observed
and the change in weight was not modified in the mice
treated with this inhibitor.

EXAMPLE 2

The aim of this example is to demonstrate the
15 topical anti-irritant activity *in vivo* of
 N^G, N^G -dimethylarginine administered for preventive
purposes.

The test used to evaluate this activity is
the same as that used in Example 1.

20 The exact operating procedure is the
following: 5 mice are first treated with a gel
comprising, as sole active agent, 1% by weight of
 N^G, N^G -dimethylarginine by one topical application per
day to one of their ears for 4 days. No increase in the
25 thickness of the ear of the mice thus treated is
observed. Next, there is topically applied to the ear
of these 5 mice previously treated with N^G, N^G -
dimethylarginine (group A) and to the ear of 5

untreated mice (group B), at time $t=0$, 20 μ l of an acetone solution comprising 0.01% by weight of 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo[b]thiophenecarboxylic acid. The oedematous response is quantified by measurement of the thickness of the ear. The results are then expressed as % increase in the thickness of the mouse ear compared with the increase in thickness observed on the other ear which, for its part, was treated (under the same conditions as above), with only an acetone solution without active agent (control or reference ear and oedema).

By comparing groups A and B, the results obtained are the following:

N^G, N^G -dimethylarginine applied topically once per day for 4 days before the application of the product having an irritant character (2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo[b]thiophenecarboxylic acid) reduces by 24% the amplitude and by 50% the area under the curve of the response induced by the product having an irritant character (the curve corresponding to the thickness of the ear as a function of the days for the reading).

EXAMPLE 3

The aim of this example is to demonstrate the topical anti-irritant activity *in vivo* of N^G -monomethyl-L-arginine (L-NMMA) used for curative purposes.

The test used to evaluate this activity is the same as that used in Example 1.

The exact operating procedure is the following: 10 mice are first treated with the active product having an irritant character by topically applying to one of their ears at time $t=0$ with 20 μl of an acetone solution containing 0.01% by weight of 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo[b]thiophenecarboxylic acid. A gel comprising 1% by weight of L-NMMA is topically applied to 5 (=group 2) of the 10 mice thus treated 6 hours after the application of the product having an irritant character, once per day for 5 days. The 5 mice which were not treated with L-NMMA constitute group 1. The oedematous response is quantified by measurement of the thickness of the ear. The results are then expressed as % increase in the thickness of the mouse ear compared to the increase in thickness observed on the other ear which, for its part, was treated (under the same conditions as above) with only an acetone solution without active agent (control or reference ear).

The results obtained are as follows:

After 5 days of treatment, the increase in the thickness of the mouse ear is at its maximum (100%) for group 1 and is 72% for group 2.

The results clearly demonstrate a 28% inhibition of the ear oedema for the mice treated with this NO-synthase inhibitor.

L-NMMA reduces by 51% the area under the curve of the response induced by the product having an irritant character (the curve corresponding to the thickness of the ear as a function of the days for the reading).

If the same treatment is carried out by applying, in place of L-NMMA, 1% or 5% betaine or 1% N^G,N^G-dimethyl-L-arginine (symmetric dimethyl-L-arginine, called SDMA), a 9, 16 and 7% inhibition of the oedema of the ear is observed, respectively, for the mice treated with these products which are not NO-synthase inhibitors (see especially for SDMA: The Lancet, Vol. 339: 572-575). A 24, 13 and 27% reduction in the area under the curve of the response induced by the product having an irritant character is also observed respectively (the curve corresponding to the thickness of the ear as a function of the days for the reading).

EXAMPLE 4

Compositions in accordance with the invention, provided in the form of a lotion, a gel and a cream for topical use, are illustrated here.

LOTION

	% by weight
Disodium EDTA	0.1
Poloxamer 182	0.2
Water	qs 100
Ethoxydiglycol	5

1

% by weight

0.1

0.2

qs 100

3

5

1

% by weight

0.1

0.2

qs 100

0.3

3

10

5

5

1

% by weight

 10^{-2} 10^{-2}

	Glycerol stearate	2.00
	Polysorbate 60 (Tween 60 sold by the company ICI)	1.00
	Stearic acid	1.40
5	Triethanolamine	0.70
	Carbomer	0.40
	Liquid fraction of shea butter	12.00
	Perhydrosqualene	12.00
	Antioxidant	0.05
10	Perfume	0.50
	Preservative	0.30
	Water	qs 100
	<u>LOTION</u>	
	Adapalène TM	0.010 g
15	N ^G -monomethyl-L-arginine (NMMA)	0.100 g
	Polyethyleneglycol (PEG 400)	69.890 g
	Ethanol 95%	30.000 g

03804708-032797

CLAIMS

1. Use of an effective quantity of at least one NO-synthase inhibitor in a cosmetic composition or for the manufacture of a pharmaceutical composition, this inhibitor or the pharmaceutical composition being intended to reduce the cutaneous irritant effect of products topically used in the cosmetic or pharmaceutical field.

2. Use according to the preceding claim, characterized in that at least one NO-synthase inhibitor is used at a concentration by weight of between $10^{-6}\%$ and 10% of the total weight of the composition and preferably between $10^{-4}\%$ and 1% of the total weight of the composition.

3. Use according to one of the preceding claims, characterized in that the product having an irritant character applied topically to the skin, the scalp, the nails or the mucous membranes is a compound chosen from preservatives, surfactants, perfumes, solvents or propellents.

4. Use according to either of Claims 1 and 2, characterized in that the product having an irritant character topically applied to the skin, the scalp, the nails or the mucous membranes is a compound chosen from some sunscreens, α -hydroxy acids, β -hydroxy acids, such as salicylic acid and its derivatives, α -keto acids, β -keto acids, retinoids, anthralins, anthranoids, peroxides, minoxidil and its derivatives, lithium

08894788 000296

salts, antiproliferative agents, vitamin D and its derivatives, vitamin B9 and its derivatives, hair dyes or colorants, capsaicin, perfuming alcoholic solutions, antiperspirants, depilatory or permanent waving active agents, depigmenting agents, antilouse active agents, detergents and propigmenting agents.

5 5. Use according to the preceding claim, characterized in that the product having an irritant character is chosen from retinoids.

10 6. Use according to the preceding claim, characterized in that the retinoids are chosen from all-trans-retinoic acid, 13-cis-retinoic acid, 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo[b]thiophenecarboxylic acid, 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid, TazarotèneTM.

15 7. Use according to Claim 4, characterized in that the vitamin D and its derivatives are chosen from vitamin D₃, vitamin D₂, 1,25-diOH vitamin D₃ (calcitriol), calcipotriol, 1,24-diOH vitamin D₃ (such as tacalcitol), 24,25-diOH vitamin D₃, 1-OH vitamin D₂, 1,24-diOH vitamin D₂.

20 8. Use according to Claim 4, characterized in that the salicylic acid derivatives are chosen from 5-n-octanoylsalicylic acid and 5-n-dodecanoylsalicylic acid or their esters.

25 9. Use according to any one of the preceding claims, characterized in that the NO-synthase inhibitors are inhibitors of constitutive NO-synthase.

10. Use according to the preceding claim, characterized in that the inhibitors of constitutive NO-synthase are inhibitors of endothelial NO-synthase.

11. Use according to either of Claims 9 and
5 10, characterized in that the NO-synthase inhibitors are chosen from N^G-monomethyl-L-arginine (NMMA), the methyl ester of N^G-nitro-L-arginine (NAME), N^G-nitro-L-arginine (NNA), N^G-amino-L-arginine (NAA),
10 N^G,N^G-dimethylarginine (asymmetric dimethylarginine, called ADMA).

12. Use according to the preceding claim, characterized in that the NO-synthase inhibitors are chosen from the methyl ester of N^G-nitro-L-arginine, N^G,N^G-dimethylarginine, N^G-nitro-L-arginine and N^G-
15 monomethyl-L-arginine (NMMA).

13. Use according to any one of the preceding claims, characterized in that the NO-synthase inhibitors are used alone or as a mixture.

14. Use according to any one of the
20 preceding claims, characterized in that the NO-synthase inhibitor is used by the topical route.

15. Cosmetic or pharmaceutical composition for topical use, characterized in that it comprises, in a cosmetically or pharmaceutically acceptable medium,
25 an effective quantity of at least one NO-synthase inhibitor and at least one product capable of causing skin irritation.

16. Composition according to the preceding

claim, characterized in that the pharmaceutical composition is a dermatological composition.

17. Composition according to either of Claims 15 and 16, characterized in that it comprises at least one NO-synthase inhibitor at a concentration by weight of between $10^{-6}\%$ and 10% of the total weight of the composition and preferably between $10^{-4}\%$ and 1% of the total weight of the composition.

18. Composition according to one of Claims 15 to 17, characterized in that the product capable of causing skin irritation is chosen from preservatives, surfactants, perfumes, solvents or propellents.

19. Composition according to one of Claims 15 to 18, characterized in that the product capable of causing skin irritation is chosen from sunscreens, α -hydroxy acids, β -hydroxy acids, such as salicylic acid and its derivatives, α -keto acids, β -keto acids, retinoids, anthralins, anthranoids, peroxides, minoxidil and its derivatives, lithium salts, antiproliferative agents, vitamin D and its derivatives, vitamin B9 and its derivatives, hair dyes or colorants, capsaicin, perfuming alcoholic solutions, antiperspirants, depilatory or permanent waving active agents, depigmenting agents, antilouse active agents, detergents and propigmenting agents.

20. Composition according to the preceding claim, characterized in that the product capable of causing skin irritation is chosen from retinoids.

00004788 033797

21. Composition according to the preceding claim, characterized in that the retinoids are chosen from all-trans-retinoic acid, 13-cis-retinoic acid, 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-
 5 6-benzo[b]thiophenecarboxylic acid, 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid, TazarotèneTM.

22. Composition according to Claim 19, characterized in that the vitamin D and its derivatives are chosen from vitamin D₃, vitamin D₂, 1,25-diOH
 10 vitamin D₃ (calcitriol), calcipotriol, 1,24-diOH vitamin D₃ such as tacalcitol, 24,25-diOH vitamin D₃, 1-OH vitamin D₂, 1,24-diOH vitamin D₂.

23. Composition according to Claim 19, characterized in that the salicylic acid derivatives
 15 are chosen from 5-n-octanoylsalicylic acid and 5-n-dodecanoylsalicylic acid or their derivatives.

24. Composition according to one of Claims 15 to 23, characterized in that the NO-synthase inhibitors are inhibitors of constitutive NO-synthase.

20 25. Composition according to the preceding claim, characterized in that the inhibitors of constitutive NO-synthase are inhibitors of endothelial NO-synthase.

26. Composition according to either of
 25 Claims 24 and 25, characterized in that the NO-synthase inhibitors are chosen from N^G-monomethyl-L-arginine (NMMA), the methyl ester of N^G-nitro-L-arginine (NAME), N^G-nitro-L-arginine (NNA), N^G-amino-L-arginine (NAA),

N^G, N^G -dimethylarginine (asymmetric dimethylarginine, called ADMA).

27. Composition according to the preceding claim, characterized in that the NO-synthase inhibitors
5 are chosen from the methyl ester of N^G -nitro-L-arginine, N^G, N^G -dimethylarginine, N^G -nitro-L-arginine and N^G -monomethyl-L-arginine (NMMA).

28. Composition according to any one of Claims 15 to 27, characterized in that the NO-synthase
10 inhibitors are used alone or as a mixture.

29. Composition according to any one of Claims 15 to 28, characterized in that it is formulated so as to be applied to the skin, the scalp and/or the mucous membranes.

30. Process of cosmetic treatment,
15 characterized in that it uses the cosmetic composition according to one of Claims 15 to 29.

00041788-082797

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: NITRIC OXIDE SYNTHASE INHIBITORS, the specification of which is ☐ attached and/or ☐ was filed as United States Application Serial No. _____ on _____ and was amended on _____ (if applicable); or was filed as PCT International Application Number PCT/FR96/00296 on February 26, 1996 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below or any provisional application(s) under 35 U.S.C. § 111(b) and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America, or any provisional applications filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
France	95-02267	February 27, 1995	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)

I hereby appoint the following attorney and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.**, Reg. No. 22,540; Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsvold, Reg. No. 22,593; Tipton D. Jennings, IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Hefter, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,098; Herbert H. Mintz, Reg. No. 26,691; C. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,610; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 20,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romary, Reg. No. 26,331; Bruce C. Zotter, Reg. No. 27,680; Dennis P. O'Reilly, Reg. No. 27,932; Allen M. Sokal, Reg. No. 26,695; Robert D. Bajefsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; Thomas L. Irving, Reg. No. 28,619; Charles E. Lipsey, Reg. No. 28,165; Thomas W. Winland, Reg. No. 27,605; Basil J. Lewis, Reg. No. 28,818; Martin I. Fuchs, Reg. No. 28,508; E. Robert Yoches, Reg. No. 30,120; Barry W. Graham, Reg. No. 29,924; Susan Haberman Griffen, Reg. No. 30,907; Richard B. Racine, Reg. No. 30,415; Thomas H. Jenkins, Reg. No. 30,857; Robert E. Converse, Jr., Reg. No. 27,432; Clair X. Mullen, Jr., Reg. No. 20,348; Christopher P. Foley, Reg. No. 31,354; John C. Paul, Reg. No. 30,413; Roger D. Taylor, Reg. No. 28,992; David M. Kelly, Reg. No. 30,953; Kenneth J. Meyers, Reg. No. 25,146; Carol P. Einaudi, Reg. No. 32,220; Walter Y. Boyd, Jr., Reg. No. 31,738; Steven M. Anzalone, Reg. No. 32,095; Jean B. Fordis, Reg. No. 32,984; Barbara C. McCurdy, Reg. No. 32,120; James K. Hammond, Reg. No. 31,964; Richard V. Burgujian, Reg. No. 31,744; J. Michael Jakes, Reg. No. 32,824; Dirk D. Thomas, Reg. No. 32,600; Thomas W. Banks, Reg. No. 32,719; Christopher P. Isaac, Reg. No. 32,616; Bryan C. Diner, Reg. No. 32,409; M. Paul Barker, Reg. No. 32,013; Andrew Chanho Sonu, Reg. No. 33,457; David S. Forman, Reg. No. 33,694; Vincent P. Kovalick, Reg. No. 32,867; and

Please address all correspondence to **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.** 1300 I Street, N.W., Washington, D.C. 20005, Telephone No. (202) 408-4000.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor <u>Paolo Giacomoni</u>	Inventor's Signature <u>Paolo Giacomoni</u>	Date <u>24th July 1997</u>
Residence 7 bis, rue des Pommiers, 91400 ORSAY, FRANCE <u>FRX</u>	Country of Citizenship: France	
Post Office Address 7 bis, rue des Pommiers, 91400 ORSAY, FRANCE		